does the helios trial indicate a paradigm shift in the management of cll?
Published 9 years ago • 159 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
2:00
does the helios trial indicate a paradigm shift in the management of cll?
-
5:00
outcomes from the resonate 2 and helios trials—clinical impact
-
7:37
resonate, resonate-2 and helios: three major clinical trials in cll research
-
2:16
the role of covalent btkis in the management of cll
-
3:15
what is leukemia?
-
53:03
talk by professor paul moss - cll treatment in 2022/23
-
13:28
chronic lymphocytic leukemia (cll): symptoms (ex. skin blisters), diagnosis and treatment (vit d?)
-
5:03
understanding patient perspectives in cll treatment
-
0:57
unanswered questions in frontline cll treatment
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
1:38
genetic heterogeneity of retinitis pigmentosa
-
59:17
chronic lymphocytic leukemia (cll) - diagnosis, prognosis and management with ibrutinib
-
1:42
what are the goals of cll treatment?
-
17:52
diagnosis and initial treatment of cll
-
24:22
highlight of cll-related 2016 fda approvals: venetoclax
-
3:26
the current status of cll treatment and how clinical practice will change
-
1:15
the current role of acalabrutinib in the treatment of cll
-
3:23
advances in the treatment of cll at asco 2015
-
5:29
helios trial: ibrutinib combined with br for previously treated cll/sll
-
10:04
chromosomal abnormalities and treatment decisions in chronic lymphocytic leukemia
-
11:28
adverse events of ibrutinib in chronic lymphocytic leukemia
-
1:58
the future role of mrd measurement in cll